ACT up +0.69% percent Today $ACT High is at 247.85 and the Low 242.70 with current volume of 591,307.
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.91 (-0.05), ACT: 245.85 (-0.06), JAZZ: 171.99 (+1.19), UNH: 94.52 (+0.91), CELG: 107.64 (+1.19), CELGZ: 3.17 (-0.07)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 245.85 (-0.06), VRX: 127.52 (+1.41), IRWD: 13.74 (-0.10), AUXL: 32.76 (+0.01)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 195.29 (-0.71), ACT: 245.85 (-0.06), MSFT: 48.97 (+0.29), VZ: 51.02 (+0.16)
Company News for November 06, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:10AM CST
Companies in the News are: ACT,CTSH,COV,TW
ACT: 245.85 (-0.06), COV: 92.54 (+0.46), CTSH: 53.72 (+0.10), TW: 113.74 (-0.92)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 195.29 (-0.71), VRX: 127.52 (+1.41), ACT: 245.85 (-0.06), SHPG: 200.22 (+1.64), ABBV: 63.62 (+2.12)
Jim Cramer's Top Stock Picks: LMT MPC ACT
at The Street - Thu Nov 06, 5:00AM CST
Marathon is Cramer's favorite refiner and Actavis is a great drug maker.
LMT: 186.75 (+0.60), ACT: 245.85 (-0.06), MPC: 94.14 (+0.06)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 245.85 (-0.06), LMT: 186.75 (+0.60), XOM: 96.47 (-0.12), ILMN: 188.95 (+2.60), AKS: 6.58 (-0.04), KORS: 69.69 (-0.26), PAYX: 47.42 (+0.09), RIG: 29.59 (-0.12), EOG: 99.82 (+0.27), COST: 137.30 (-0.41), TWTR: 40.04 (-0.27), OXY: 88.34 (+0.30), KO: 42.38 (+0.06), SEAS: 18.51 (+0.12), TMO: 116.89 (+0.29), NUE: 53.84 (-0.34), TRIP: 73.09 (-0.56), DISCA: 32.25 (-0.37), CHUY: 22.99 (+0.97), LB: 75.99 (+0.38), GEO: 40.91 (-0.49), ESV: 40.45 (-0.86), MPC: 94.14 (+0.06), BAX: 70.53 (-0.08), MRK: 59.10 (-0.24), EXPE: 86.00 (+0.89), STI: 39.57 (-0.09)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 195.29 (-0.71), ACT: 245.85 (-0.06), SWKS: 60.95 (+1.07), AKRX: 35.23 (-1.36), SLXP: 93.93 (+2.46), AAPL: 109.03 (+0.02)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 195.29 (-0.71), VRX: 127.52 (+1.41), ACT: 245.85 (-0.06)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 1:10PM CST
The following Actavis (ACT) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
ACT: 245.85 (-0.06)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.33 (+1.27), ACT: 245.85 (-0.06), MYL: 53.77 (+0.66), TEVA: 58.05 (+0.35)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 195.29 (-0.71), ACT: 245.85 (-0.06), TEVA: 58.05 (+0.35)
Actavis reports 3Q loss
Automated Insights - Wed Nov 05, 6:36AM CST
DUBLIN 2, Ireland (AP) _ Actavis PLC (ACT) on Wednesday reported a third-quarter loss of $1.04 billion.
ACT: 245.85 (-0.06)
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015
PR Newswire - Wed Nov 05, 5:45AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R. Todd Joyce will retire from Actavis in early 2015. To ensure a smooth transition, the Company said Mr. Joyce will continue as the Company's CFO until a successor is named. Actavis has engaged a leading executive search firm to identify a successor.
ACT: 245.85 (-0.06)
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
PR Newswire - Wed Nov 05, 5:30AM CST
Actavis plc (NYSE: ACT) today reported net revenue increased 83 percent to $3.7 billion for the third quarter ended September 30, 2014, compared to $2.0 billion in the third quarter 2013. On a non-GAAP basis, diluted earnings per share for the third quarter 2014 increased to $3.19, compared to $2.09 per diluted share in the third quarter 2013. GAAP loss per diluted share for the third quarter 2014 was $3.95, compared to GAAP earnings per share of $0.49 in the prior year period.
ACT: 245.85 (-0.06)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.29 (-0.71), BIIB: 324.90 (+4.15), VRX: 127.52 (+1.41), ACT: 245.85 (-0.06), JAZZ: 171.99 (+1.19), ALXN: 193.65 (-0.16), CELG: 107.64 (+1.19)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 241.56 (+1.36), ACT: 245.85 (-0.06), FEYE: 32.15 (+1.53), AWAY: 29.44 (+0.23), CYBR: 34.46 (+1.75), JAZZ: 171.99 (+1.19), TRIP: 73.09 (-0.56), PANW: 109.32 (+2.30), ATHM: 44.05 (+0.42)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.33 (+1.27), ACT: 245.85 (-0.06), ARIA: 6.26 (+0.18), HSP: 56.03 (-0.29)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 245.85 (-0.06), ECYT: 6.10 (+0.07), MRK: 59.10 (-0.24), HSP: 56.03 (-0.29)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 109.31 (-3.46), ACT: 245.85 (-0.06), PRGO: 155.85 (+0.08), ALNY: 98.79 (+2.95)
Recent News posted below.
Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/
ACT Actavis Inc Recent Headline News
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 68.91 (-0.05), ACT: 245.85 (-0.06), JAZZ: 171.99 (+1.19), UNH: 94.52 (+0.91), CELG: 107.64 (+1.19), CELGZ: 3.17 (-0.07)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 245.85 (-0.06), VRX: 127.52 (+1.41), IRWD: 13.74 (-0.10), AUXL: 32.76 (+0.01)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 195.29 (-0.71), ACT: 245.85 (-0.06), MSFT: 48.97 (+0.29), VZ: 51.02 (+0.16)
Company News for November 06, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 9:10AM CST
Companies in the News are: ACT,CTSH,COV,TW
ACT: 245.85 (-0.06), COV: 92.54 (+0.46), CTSH: 53.72 (+0.10), TW: 113.74 (-0.92)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 195.29 (-0.71), VRX: 127.52 (+1.41), ACT: 245.85 (-0.06), SHPG: 200.22 (+1.64), ABBV: 63.62 (+2.12)
Jim Cramer's Top Stock Picks: LMT MPC ACT
at The Street - Thu Nov 06, 5:00AM CST
Marathon is Cramer's favorite refiner and Actavis is a great drug maker.
LMT: 186.75 (+0.60), ACT: 245.85 (-0.06), MPC: 94.14 (+0.06)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 245.85 (-0.06), LMT: 186.75 (+0.60), XOM: 96.47 (-0.12), ILMN: 188.95 (+2.60), AKS: 6.58 (-0.04), KORS: 69.69 (-0.26), PAYX: 47.42 (+0.09), RIG: 29.59 (-0.12), EOG: 99.82 (+0.27), COST: 137.30 (-0.41), TWTR: 40.04 (-0.27), OXY: 88.34 (+0.30), KO: 42.38 (+0.06), SEAS: 18.51 (+0.12), TMO: 116.89 (+0.29), NUE: 53.84 (-0.34), TRIP: 73.09 (-0.56), DISCA: 32.25 (-0.37), CHUY: 22.99 (+0.97), LB: 75.99 (+0.38), GEO: 40.91 (-0.49), ESV: 40.45 (-0.86), MPC: 94.14 (+0.06), BAX: 70.53 (-0.08), MRK: 59.10 (-0.24), EXPE: 86.00 (+0.89), STI: 39.57 (-0.09)
Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 195.29 (-0.71), ACT: 245.85 (-0.06), SWKS: 60.95 (+1.07), AKRX: 35.23 (-1.36), SLXP: 93.93 (+2.46), AAPL: 109.03 (+0.02)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 195.29 (-0.71), VRX: 127.52 (+1.41), ACT: 245.85 (-0.06)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Wed Nov 05, 1:10PM CST
The following Actavis (ACT) conference call took place on November 5, 2014, 08:00 AM ET. This is a transcript of that earnings call:
ACT: 245.85 (-0.06)
Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.33 (+1.27), ACT: 245.85 (-0.06), MYL: 53.77 (+0.66), TEVA: 58.05 (+0.35)
Actavis plc's Strong Third-Quarter Earnings Reflect Its Acquisition Bonanza
George Budwell, The Motley Fool - Motley Fool - Wed Nov 05, 8:36AM CST
Healthcare stocks, in general, and biopharmas, in particular, have seen some of their best returns in decades, fueled mainly by a wave of new drugs gaining approval and an aging population in the U.S. The growth story of specialty and generic...
AGN: 195.29 (-0.71), ACT: 245.85 (-0.06), TEVA: 58.05 (+0.35)
Actavis reports 3Q loss
Automated Insights - Wed Nov 05, 6:36AM CST
DUBLIN 2, Ireland (AP) _ Actavis PLC (ACT) on Wednesday reported a third-quarter loss of $1.04 billion.
ACT: 245.85 (-0.06)
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015
PR Newswire - Wed Nov 05, 5:45AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Chief Financial Officer R. Todd Joyce will retire from Actavis in early 2015. To ensure a smooth transition, the Company said Mr. Joyce will continue as the Company's CFO until a successor is named. Actavis has engaged a leading executive search firm to identify a successor.
ACT: 245.85 (-0.06)
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19
PR Newswire - Wed Nov 05, 5:30AM CST
Actavis plc (NYSE: ACT) today reported net revenue increased 83 percent to $3.7 billion for the third quarter ended September 30, 2014, compared to $2.0 billion in the third quarter 2013. On a non-GAAP basis, diluted earnings per share for the third quarter 2014 increased to $3.19, compared to $2.09 per diluted share in the third quarter 2013. GAAP loss per diluted share for the third quarter 2014 was $3.95, compared to GAAP earnings per share of $0.49 in the prior year period.
ACT: 245.85 (-0.06)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.29 (-0.71), BIIB: 324.90 (+4.15), VRX: 127.52 (+1.41), ACT: 245.85 (-0.06), JAZZ: 171.99 (+1.19), ALXN: 193.65 (-0.16), CELG: 107.64 (+1.19)
Stocks End Mixed; Jazz Pharma Rises After Hours
at Investor's Business Daily - Tue Nov 04, 4:11PM CST
Stocks closed mixed, as earnings reports shook some stocks after the bell. The Nasdaq and S&P 500 dropped 0.3%, and the Dow Jones industrial average gained 0.1%. Volume was higher on the NYSE and lower on the Nasdaq, according to preliminary figures....
TSLA: 241.56 (+1.36), ACT: 245.85 (-0.06), FEYE: 32.15 (+1.53), AWAY: 29.44 (+0.23), CYBR: 34.46 (+1.75), JAZZ: 171.99 (+1.19), TRIP: 73.09 (-0.56), PANW: 109.32 (+2.30), ATHM: 44.05 (+0.42)
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.33 (+1.27), ACT: 245.85 (-0.06), ARIA: 6.26 (+0.18), HSP: 56.03 (-0.29)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 245.85 (-0.06), ECYT: 6.10 (+0.07), MRK: 59.10 (-0.24), HSP: 56.03 (-0.29)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 109.31 (-3.46), ACT: 245.85 (-0.06), PRGO: 155.85 (+0.08), ALNY: 98.79 (+2.95)
